SCHEMBL10247836

SCHEMBL10247836

CCOC(=O)CCCn1ccc(-c2ccccc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
HTT P42858 1/20 0.52
GAA P10253 1/20 0.52
FAAH O00519 4/20 0.47
TNF P01375 2/20 0.47
PARP1 P09874 1/20 0.45
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
GABRA4 P48169 1/20 0.44
GABRE P78334 1/20 0.44
GABRA6 Q16445 1/20 0.44
GABRG1 Q8N1C3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412586 0.88 FAAH (0.51) ALDH1A1GAAFAAHTSHRHSD17B10
SCHEMBL413536 0.86 GABRP (0.48) ALDH1A1TNFGABRPGABRDGABRA1
SCHEMBL5282599 0.84 HTT (0.64) ALDH1A1HTTGAATSHRCYP1A2
SCHEMBL10247832 0.82 GABRA1 (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3046024 0.81 FAAH (0.44) ALDH1A1FAAHTNFEP300LMNA
SCHEMBL3039018 0.79 HDAC3 (0.50) ALDH1A1FAAHTNFHSD17B10EP300
SCHEMBL18338543 0.79 THRB (0.45) ALDH1A1GAATNFCYP1A2HSD17B10
SCHEMBL563558 0.77 GAA (0.52) ALDH1A1GAAFAAHTNFPDE5A
SCHEMBL17261550 0.76 GABRP (0.51) ALDH1A1HTTGAAGABRPGABRD
SCHEMBL6431328 0.76 KMT2A (0.55) ALDH1A1TSHRCYP1A2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 ALDH1A1 455/4885HTT 2001/4885GAA 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.